User-defined tumor antigen (UDTA)

The term User-defined tumor antigen refers to a non-specific, placeholder classification used in therapeutic development, particularly within the fields of adoptive cell transfer and personalized immunotherapy. Rather than representing a single biological entity, it signifies a framework where the specific molecular target—such as a neoantigen or a lineage-specific protein—is selected based on the unique genetic and proteomic profile of a patient's malignancy. This approach is central to the design of chimeric antigen receptor (CAR) T-cell therapies and bespoke cancer vaccines, where the treatment is engineered to home in on a target identified through diagnostic sequencing. Because the target is variable, the biological function and disease role are entirely dependent on the specific antigen chosen for a given clinical application. While this flexibility allows for highly precise targeting of heterogeneous tumors, it also presents significant challenges regarding standardized safety profiling and the potential for off-target effects if the chosen antigen is expressed in healthy tissues.

Other names

Patient-specific tumor antigenCustom tumor antigenNeoantigen (personalized)Tumor-associated antigen (unspecified)

The mechanism involves the engineering of immune cells (such as CAR-T or TCR-T cells) or the formulation of vaccines to recognize and eliminate cells expressing a specific antigen identified from an individual patient's tumor profile.